

IVIEW Therapeutics was awarded SBIR Innovative grant by NIH's National Institute of Allergy and Infectious Diseases (NIAID)

March 26, 2018

Doylestown, Pennsylvania--IVIEW Therapeutics Inc., an innovative specialty pharmaceutical company focusing on topical drug and medical device development, today announced that it has received a Small Business Innovation Research (SBIR) Award from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH). The phase I SBIR grant is awarded to IVIEW's project titled "In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis". "The PI proposes to develop a long acting in situ gel nasal spray containing povidone iodine in combination with budesonide for the treatment of chronic rhinosinusitis. If successful, this combination of a long acting broad anti-infective with an anti-inflammatory agent is likely to have a significant impact on treatment of patients with chronic rhinosinusitis (CSR)", commented by the NIH reviewers. Dr. Bo Liang, President & Director at IVIEW comments, "we will progress quickly through pre-clinical studies and move into proof-of-concept human trials with the innovative extended release formulation to achieve minimized irritation to nasal cavity with long acting therapeutic effect."

About IVIEW Therapeutics Inc.

IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focusing on topical drug development on specific therapeutic areas (i.e. ophthalmology, dermatology, Otolaryngology, Gynecology). It's headquartered at Pennsylvania Biotechnology Center of Bucks County and has set up its China headquarter in Hengqin, Zhuhai City, Guangdong Province and manufacturing center in Wuhu, China for develop the products in the China market. Please visit: www.iviewtherapeutics.com for more details.